Literature DB >> 15147568

Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice.

Winston L Hutchinson1, Jeff Herbert, Marina Botto, Mark B Pepys.   

Abstract

During induction of reactive systemic amyloid A protein (AA) amyloidosis in mice, either by chronic inflammation or by severe acute inflammation following injection of amyloid enhancing factor, the earliest deposits form in a perifollicular distribution in the spleen. Because the splenic follicular localization of immune complexes and of the scrapie agent are both complement dependent in mice, we investigated the possible complement dependence of AA amyloid deposition. In preliminary experiments, substantial depletion of circulating C3 by cobra venom factor had little effect on experimental amyloid deposition. More importantly, mice with targeted deletion of the genes for C1q or for both factor B and C2, and therefore unable to sustain activation, respectively, of either the classical complement pathway or both the classical and alternative pathways, showed amyloid deposition similar to wild type controls. Complement activation by either the classical or alternative pathways is thus not apparently necessary for the experimental induction of systemic AA amyloid in mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147568      PMCID: PMC1782488          DOI: 10.1111/j.1365-2567.2004.01881.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  Complement dependence of localisation of aggregated IgG in germinal centres.

Authors:  M Papamichail; C Gutierrez; P Embling; P Johnson; E J Holborow; M B Pepys
Journal:  Scand J Immunol       Date:  1975       Impact factor: 3.487

2.  EXPERIMENTAL AMYLOIDOSIS: STUDIES WITH A MODIFIED CASEIN METHOD, CASEIN HYDROLYSATE AND GELATIN.

Authors:  D T JANIGAN
Journal:  Am J Pathol       Date:  1965-07       Impact factor: 4.307

3.  Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene.

Authors:  M Botto; P N Hawkins; M C Bickerstaff; J Herbert; A E Bygrave; A McBride; W L Hutchinson; G A Tennent; M J Walport; M B Pepys
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

4.  A primed state exists in vivo following histological regression of amyloidosis.

Authors:  P N Hawkins; M B Pepys
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

5.  Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis.

Authors:  D R Booth; M Sunde; V Bellotti; C V Robinson; W L Hutchinson; P E Fraser; P N Hawkins; C M Dobson; S E Radford; C C Blake; M B Pepys
Journal:  Nature       Date:  1997-02-27       Impact factor: 49.962

6.  Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.

Authors:  P N Hawkins; G A Tennent; P Woo; M B Pepys
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

7.  Use of N-bromosuccinimide for the iodination of proteins for radioimmunoassay.

Authors:  P Reay
Journal:  Ann Clin Biochem       Date:  1982-03       Impact factor: 2.057

8.  Further characterization of amyloid-enhancing factor.

Authors:  M A Axelrad; R Kisilevsky; J Willmer; S J Chen; M Skinner
Journal:  Lab Invest       Date:  1982-08       Impact factor: 5.662

9.  Redistribution of amyloid deposits.

Authors:  T Shirahama; A S Cohen
Journal:  Am J Pathol       Date:  1980-06       Impact factor: 4.307

10.  An improved method for the isolation from Naja naja venom of cobra factor (CoF) free of phospholipase A.

Authors:  M B Pepys; C Tompkins; A D Smith
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

View more
  2 in total

Review 1.  Research-Relevant Conditions and Pathology of Laboratory Mice, Rats, Gerbils, Guinea Pigs, Hamsters, Naked Mole Rats, and Rabbits.

Authors:  Timothy K Cooper; David K Meyerholz; Amanda P Beck; Martha A Delaney; Alessandra Piersigilli; Teresa L Southard; Cory F Brayton
Journal:  ILAR J       Date:  2021-12-31       Impact factor: 1.521

2.  C1q as a target molecule to treat human disease: What do mouse studies teach us?

Authors:  Kristina Schulz; Marten Trendelenburg
Journal:  Front Immunol       Date:  2022-08-03       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.